Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported a routine tax-related share disposition. On May 26, 2026, 1,168 shares of common stock were withheld to cover tax obligations arising from the vesting of restricted stock units granted on February 26, 2024. After this withholding, Kim directly holds 364,632 common shares.
Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of common stock. On May 27, 2026, he sold 945 shares at a weighted-average price of $17.60 per share to satisfy tax withholding obligations from vested restricted stock units. After this transaction, Gao directly held 992,062 shares of Fulgent Genetics common stock, so the sale represents only a small fraction of his overall stake.
Fulgent Genetics, Inc. insider Ming Hsieh filed Amendment No. 5 to update his ownership in the company’s common stock. He beneficially owns 8,872,539 shares, representing 32.26% of the 27,493,435 shares outstanding as of May 22, 2026. The Ming Hsieh Trust beneficially owns 7,895,115 shares, or 28.72% of the class.
Since the prior amendment, Hsieh acquired additional shares solely through vesting of equity awards; on May 26, 2026, 5,496 RSU shares vested, with 2,949 shares withheld for taxes, and no cash consideration was paid. A total of 1,000,000 trust shares are pledged under a pre-paid forward arrangement and 5,760,733 trust shares secure a credit facility, so the lender may dispose of these if there is a default. Hsieh indicates he holds the stake for general investment purposes but may increase or decrease his holdings over time.
Fulgent Genetics, Inc. director and Chief Executive Officer Ming Hsieh reported a routine tax withholding event related to equity compensation. Upon vesting of restricted stock units granted on February 26, 2024, 2,949 shares of common stock were withheld at $17.67 per share to satisfy tax obligations, leaving him with 897,685 directly held shares.
He also reports substantial indirect holdings, including shares held by The Ming Hsieh Trust, the Dynasty Trust, a Uniform Transfers to Minor Act account, and an immediate family member in the same household, with individual positions such as 7,895,115 shares and 220,816 shares held via trusts.
Fulgent Genetics reported interim Phase 2 results for its cancer drug candidate FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma. The data come from an open-label, randomized study presented in a full abstract at ASCO 2026.
Among 42 efficacy-evaluable patients, the combination showed an objective response rate of 60%, with median progression-free survival of 7.2 months across two dosing arms. Median duration of response was 7.4 months, and over half of responders were still responding at the data cut-off of December 20, 2025.
The safety profile was described as favorable overall, with most treatment-related side effects in grades 1–2, though grade 3–4 events such as neutropenia, anemia, leukopenia and rash occurred, and there was one grade 5 treatment-related pneumonia. Overall survival data remain immature. The abstract is available on ASCO’s site, with final presentation slides to follow on June 1, 2026.
Fulgent Genetics director Michael Nohaile reported new equity awards. He received 5,558 shares of common stock as a grant, bringing his direct holdings to 24,578 shares. He was also granted options on 8,426 shares at an exercise price of $16.19 per share, expiring on May 13, 2036.
The 5,558 restricted stock units and the 8,426 options both vest over four years. One quarter vest 12 months after May 14, 2026, and the remainder vest in equal quarterly installments over the following 36 months, contingent on continued service with the company.
Dong Linda reported acquisition or exercise transactions in this Form 4 filing.
Fulgent Genetics director Linda Dong reported receiving 11,117 shares of Common Stock as a grant of restricted stock units at no cash cost. The award vests over four years, with 1/4 vesting 12 months after May 14, 2026 and the rest quarterly, leaving her with 38,758 directly held shares after the grant.
GROVES REGINA E reported acquisition or exercise transactions in this Form 4 filing.
Fulgent Genetics director Regina E. Groves received a grant of 11,117 shares of common stock in the form of restricted stock units. These units were awarded at no cash cost per share and increased her direct holdings to 28,099 shares after the transaction.
The restricted stock units vest over four years. One quarter of the shares vest 12 months after May 14, 2026, and the remaining three quarters vest in equal 1/16 portions at the end of every three-month period over the following 36 months, subject to her continued service with the company.
Fulgent Genetics, Inc. reported results from its 2026 annual stockholder meeting. Stockholders approved the Fulgent Genetics, Inc. 2026 Equity Incentive Plan, which authorizes issuance of 2,000,000 new shares of common stock, plus up to 1,500,000 additional shares if awards under the prior plan are forfeited or cancelled on or after the effective date.
The 2026 Plan replaces the Amended and Restated 2016 Omnibus Incentive Plan, although existing awards under the prior plan remain in effect under their current terms. Stockholders also elected four directors to serve until the 2027 annual meeting, ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers.
At the meeting, a quorum of 24,578,996 shares, or approximately 83% of the 29,747,420 shares outstanding and eligible to vote as of March 20, 2026, was present in person or by proxy, indicating strong stockholder participation.